Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Pati.

Business Wire • Jun 4, 2026

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held ​biotech Everest Medicines to develop and ‌commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.

Reuters • Jun 2, 2026

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Seeking Alpha • Jun 2, 2026

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. “Civorebrutinib represents a strategic and complementary.

Business Wire • Jun 2, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan.

Business Wire • May 27, 2026

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s.

Business Wire • May 12, 2026

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E.

Business Wire • May 7, 2026

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million. Travere also granted the underwriters of the.

Business Wire • May 7, 2026

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.

Benzinga • May 5, 2026